Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.
Identifieur interne : 000905 ( Main/Exploration ); précédent : 000904; suivant : 000906Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.
Auteurs : Kazuki Hatayama [Japon] ; Nobuyuki Nosaka [Japon] ; Mutsuko Yamada [Japon] ; Masato Yashiro [Japon] ; Yosuke Fujii [Japon] ; Hirokazu Tsukahara [Japon] ; Keyue Liu [Japon] ; Masahiro Nishibori [Japon] ; Akihiro Matsukawa [Japon] ; Tsuneo Morishima [Japon]Source :
- Journal of medical virology [ 1096-9071 ] ; 2019.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (usage thérapeutique), Antiviraux (usage thérapeutique), Association de médicaments, Cyclopentanes (usage thérapeutique), Cytokines (antagonistes et inhibiteurs), Guanidines (usage thérapeutique), Infections à Orthomyxoviridae (traitement médicamenteux), Infections à Orthomyxoviridae (virologie), Infiltration par les neutrophiles (), Inflammation (traitement médicamenteux), Injections musculaires, Mâle, Pneumopathie virale (traitement médicamenteux), Poumon (virologie), Protéine HMGB1 (immunologie), Souris, Souris de lignée C57BL.
- MESH :
- antagonistes et inhibiteurs : Cytokines.
- immunologie : Protéine HMGB1.
- traitement médicamenteux : Infections à Orthomyxoviridae, Inflammation, Pneumopathie virale.
- usage thérapeutique : Anticorps monoclonaux, Antiviraux, Cyclopentanes, Guanidines.
- virologie : Infections à Orthomyxoviridae, Poumon.
- Animaux, Association de médicaments, Infiltration par les neutrophiles, Injections musculaires, Mâle, Souris, Souris de lignée C57BL.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (therapeutic use), Antiviral Agents (therapeutic use), Cyclopentanes (therapeutic use), Cytokines (antagonists & inhibitors), Drug Therapy, Combination, Guanidines (therapeutic use), HMGB1 Protein (immunology), Inflammation (drug therapy), Injections, Intramuscular, Lung (virology), Male, Mice, Mice, Inbred C57BL, Neutrophil Infiltration (drug effects), Orthomyxoviridae Infections (drug therapy), Orthomyxoviridae Infections (virology), Pneumonia, Viral (drug therapy).
- MESH :
- chemical , antagonists & inhibitors : Cytokines.
- chemical , immunology : HMGB1 Protein.
- chemical , therapeutic use : Antibodies, Monoclonal, Antiviral Agents, Cyclopentanes, Guanidines.
- drug effects : Neutrophil Infiltration.
- drug therapy : Inflammation, Orthomyxoviridae Infections, Pneumonia, Viral.
- virology : Lung, Orthomyxoviridae Infections.
- Animals, Drug Therapy, Combination, Injections, Intramuscular, Male, Mice, Mice, Inbred C57BL.
Abstract
Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury due to the excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi. The combination of peramivir with the anti-HMGB1 mAb significantly improved survival rate whereas the anti-HMGB1 mAb alone did not affect virus proliferation in the lungs. This combination therapy also significantly ameliorated histopathological changes, neutrophil infiltration, and macrophage aggregation by inhibiting HMGB1, inflammatory cytokines, and oxidative stress. Fluorescence immunostaining showed that the anti-HMGB1 mAb inhibited HMGB1 translocation from type I alveolar epithelial cells. In summary, combining anti-HMGB1 with conventional anti-influenza therapy might be useful against severe influenza virus infection.
DOI: 10.1002/jmv.25330
PubMed: 30281823
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000238
- to stream PubMed, to step Curation: 000238
- to stream PubMed, to step Checkpoint: 000218
- to stream Ncbi, to step Merge: 000970
- to stream Ncbi, to step Curation: 000970
- to stream Ncbi, to step Checkpoint: 000970
- to stream Main, to step Merge: 000906
- to stream Main, to step Curation: 000905
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.</title><author><name sortKey="Hatayama, Kazuki" sort="Hatayama, Kazuki" uniqKey="Hatayama K" first="Kazuki" last="Hatayama">Kazuki Hatayama</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, Yosuke" sort="Fujii, Yosuke" uniqKey="Fujii Y" first="Yosuke" last="Fujii">Yosuke Fujii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Keyue" sort="Liu, Keyue" uniqKey="Liu K" first="Keyue" last="Liu">Keyue Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Matsukawa, Akihiro" sort="Matsukawa, Akihiro" uniqKey="Matsukawa A" first="Akihiro" last="Matsukawa">Akihiro Matsukawa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30281823</idno><idno type="pmid">30281823</idno><idno type="doi">10.1002/jmv.25330</idno><idno type="wicri:Area/PubMed/Corpus">000238</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000238</idno><idno type="wicri:Area/PubMed/Curation">000238</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000238</idno><idno type="wicri:Area/PubMed/Checkpoint">000218</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000218</idno><idno type="wicri:Area/Ncbi/Merge">000970</idno><idno type="wicri:Area/Ncbi/Curation">000970</idno><idno type="wicri:Area/Ncbi/Checkpoint">000970</idno><idno type="wicri:Area/Main/Merge">000906</idno><idno type="wicri:Area/Main/Curation">000905</idno><idno type="wicri:Area/Main/Exploration">000905</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.</title><author><name sortKey="Hatayama, Kazuki" sort="Hatayama, Kazuki" uniqKey="Hatayama K" first="Kazuki" last="Hatayama">Kazuki Hatayama</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, Yosuke" sort="Fujii, Yosuke" uniqKey="Fujii Y" first="Yosuke" last="Fujii">Yosuke Fujii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Keyue" sort="Liu, Keyue" uniqKey="Liu K" first="Keyue" last="Liu">Keyue Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Matsukawa, Akihiro" sort="Matsukawa, Akihiro" uniqKey="Matsukawa A" first="Akihiro" last="Matsukawa">Akihiro Matsukawa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Cyclopentanes (therapeutic use)</term><term>Cytokines (antagonists & inhibitors)</term><term>Drug Therapy, Combination</term><term>Guanidines (therapeutic use)</term><term>HMGB1 Protein (immunology)</term><term>Inflammation (drug therapy)</term><term>Injections, Intramuscular</term><term>Lung (virology)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Neutrophil Infiltration (drug effects)</term><term>Orthomyxoviridae Infections (drug therapy)</term><term>Orthomyxoviridae Infections (virology)</term><term>Pneumonia, Viral (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Cyclopentanes (usage thérapeutique)</term><term>Cytokines (antagonistes et inhibiteurs)</term><term>Guanidines (usage thérapeutique)</term><term>Infections à Orthomyxoviridae (traitement médicamenteux)</term><term>Infections à Orthomyxoviridae (virologie)</term><term>Infiltration par les neutrophiles ()</term><term>Inflammation (traitement médicamenteux)</term><term>Injections musculaires</term><term>Mâle</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Poumon (virologie)</term><term>Protéine HMGB1 (immunologie)</term><term>Souris</term><term>Souris de lignée C57BL</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HMGB1 Protein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antiviral Agents</term><term>Cyclopentanes</term><term>Guanidines</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neutrophil Infiltration</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Inflammation</term><term>Orthomyxoviridae Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Protéine HMGB1</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Inflammation</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antiviraux</term><term>Cyclopentanes</term><term>Guanidines</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Therapy, Combination</term><term>Injections, Intramuscular</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association de médicaments</term><term>Infiltration par les neutrophiles</term><term>Injections musculaires</term><term>Mâle</term><term>Souris</term><term>Souris de lignée C57BL</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury due to the excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi. The combination of peramivir with the anti-HMGB1 mAb significantly improved survival rate whereas the anti-HMGB1 mAb alone did not affect virus proliferation in the lungs. This combination therapy also significantly ameliorated histopathological changes, neutrophil infiltration, and macrophage aggregation by inhibiting HMGB1, inflammatory cytokines, and oxidative stress. Fluorescence immunostaining showed that the anti-HMGB1 mAb inhibited HMGB1 translocation from type I alveolar epithelial cells. In summary, combining anti-HMGB1 with conventional anti-influenza therapy might be useful against severe influenza virus infection.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Hatayama, Kazuki" sort="Hatayama, Kazuki" uniqKey="Hatayama K" first="Kazuki" last="Hatayama">Kazuki Hatayama</name></noRegion><name sortKey="Fujii, Yosuke" sort="Fujii, Yosuke" uniqKey="Fujii Y" first="Yosuke" last="Fujii">Yosuke Fujii</name><name sortKey="Liu, Keyue" sort="Liu, Keyue" uniqKey="Liu K" first="Keyue" last="Liu">Keyue Liu</name><name sortKey="Matsukawa, Akihiro" sort="Matsukawa, Akihiro" uniqKey="Matsukawa A" first="Akihiro" last="Matsukawa">Akihiro Matsukawa</name><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000905 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000905 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30281823
|texte= Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30281823" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |